Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials

Aclaris Therapeutics, Inc.

2025-Q2 EPS reported -$0.25 revenue$3,232,000

Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.
Cash, equivalents & securities $180.9M; runway into H2 2028 without new financing.
Phase 2a ATI-2138 met primary/key secondary endpoints; confirms tolerability in moderate-to-severe AD.
Phase 2 trial of bosakitug (anti-TSLP mAb) in AD dosing; top line expected H2 2026.
Roland Kolbeck appointed CSO replacing Joe Monahan (planned retirement through Q1 2026).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.